What does Aligos Therapeutics, Inc. do?
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic…
What is Aligos Therapeutics, Inc.'s P/E and P/B ratio?
Aligos Therapeutics, Inc. has a P/E ratio of -0.7 and a P/B ratio of 0.94.
What is Aligos Therapeutics, Inc.'s debt-to-equity ratio?
Aligos Therapeutics, Inc. has a debt-to-equity ratio of 0.11.
How much does Aligos Therapeutics, Inc. owe compared with what it owns?
Aligos Therapeutics, Inc. owes $0.52 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Aligos Therapeutics, Inc.'s Positivity rank?
Aligos Therapeutics, Inc. is ranked #1,958 of 6,774 companies globally and #521 of 4,000 in United States on PositoAI, with a Positivity Score of 22,083.
Does Aligos Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Aligos Therapeutics, Inc..
Where can I read the latest news about Aligos Therapeutics, Inc.?
Recent headlines about Aligos Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Aligos Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Aligos Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.